Sugi Predict

Sugi Predict / Compounds / SCHEMBL1368537

SCHEMBL1368537

SCHEMBL1368537

Cc1c(-c2cnn(C3CCNCC3)c2)cnc2c1N(Cc1c(F)ccc(F)c1Cl)CCN2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K3 Q8IVH8 6/20 0.46
▸ JAK2 O60674 4/20 0.46
▸ MET P08581 15/20 0.45
▸ ALK Q9UM73 5/20 0.43
▸ PLK4 O00444 2/20 0.43
▸ PRKD3 O94806 2/20 0.43
▸ ABL1 P00519 2/20 0.43
▸ LCK P06239 2/20 0.43
▸ CSF1R P07333 2/20 0.43
▸ RET P07949 2/20 0.43
▸ ROS1 P08922 2/20 0.43
▸ SRC P12931 2/20 0.43
▸ FER P16591 2/20 0.43
▸ FGFR3 P22607 2/20 0.43
▸ LTK P29376 2/20 0.43
▸ FLT3 P36888 2/20 0.43
▸ FRK P42685 2/20 0.43
▸ PTK2 Q05397 2/20 0.43
▸ MAP4K2 Q12851 2/20 0.43
▸ NTRK2 Q16620 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12146489 0.82 MAP4K3 (0.49) MAP4K3JAK2METALKPLK4
SCHEMBL12147224 0.79 JAK2 (0.43) JAK2METALKPLK4PRKD3
SCHEMBL13354667 0.76 JAK2 (0.41) MAP4K3JAK2METALKPLK4
SCHEMBL12146408 0.76 ALK (0.61) JAK2METALKPLK4PRKD3
SCHEMBL12146571 0.76 MAP4K4 (0.40) MAP4K3JAK2METALKPLK4
SCHEMBL1365989 0.76 ALK (0.50) JAK2METALKPLK4PRKD3
SCHEMBL12146375 0.75 LCK (0.41) JAK2METALKPLK4PRKD3
SCHEMBL12146728 0.75 MAP4K3 (0.43) MAP4K3JAK2METALKCHRNA4
SCHEMBL12146467 0.74 ALK (0.51) JAK2METALKPLK4PRKD3
SCHEMBL12146366 0.74 ALK (0.49) JAK2METALKPLK4PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2365809-B1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMA INC (US) 2018-07-18 — — EP disclosed
EP-2365809-B1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMA INC (US) 2018-07-18 — — EP disclosed
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. 2014-12-11 — — US disclosed
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. 2014-12-11 — — US disclosed
US-8846664-B2 Pyrazinopyrazines and derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-09-30 — — US disclosed
US-8846664-B2 Pyrazinopyrazines and derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-09-30 — — US disclosed
US-20110288078-A1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2011-11-24 — — US disclosed
US-20110288078-A1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2011-11-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors MAP3K5, MAP3K15, MAP4K2 MAP4K3 7/4885JAK2 151/4885MET 714/4885
US-20110288078-A1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS MAP3K5, MAP3K15, MAP4K2 MAP4K3 7/4885JAK2 151/4885MET 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.